238 related articles for article (PubMed ID: 28545581)
21. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
[TBL] [Abstract][Full Text] [Related]
22. High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study.
Morita-Fujita M; Katoh D; Shimomura Y; Ishikawa T
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e337-e342. PubMed ID: 31053551
[TBL] [Abstract][Full Text] [Related]
23. Serum levels of cytokines and soluble cytokine receptors in patients with metastatic renal cell carcinoma or malignant melanoma receiving IL-2/interferon-alpha combination therapy.
Fosså SD; Aamdal S; Naume B; Gallati H
Acta Oncol; 1995; 34(5):599-603. PubMed ID: 7546824
[TBL] [Abstract][Full Text] [Related]
24. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
May M; Helke C; Bock M; Hoschke B
Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
[TBL] [Abstract][Full Text] [Related]
25. Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.
Park JY; Lee JL; Baek S; Eo SH; Go H; Ro JY; Cho YM
Hum Pathol; 2014 Jul; 45(7):1437-44. PubMed ID: 24784922
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
[TBL] [Abstract][Full Text] [Related]
27. IL-6 is a survival prognostic factor in renal cell carcinoma.
Thiounn N; Pages F; Flam T; Tartour E; Mosseri V; Zerbib M; Beuzeboc P; Deneux L; Fridman WH; Debré B
Immunol Lett; 1997 Jul; 58(2):121-4. PubMed ID: 9271323
[TBL] [Abstract][Full Text] [Related]
28. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-6 induces drug resistance in renal cell carcinoma.
Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
[TBL] [Abstract][Full Text] [Related]
30. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S;
BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347
[TBL] [Abstract][Full Text] [Related]
31. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
32. Increased soluble IL-2 receptor levels during interferon and ribavirin treatment are associated with a good response in genotype 2a/2b patients with chronic hepatitis C.
Abe S; Narita R; Matsuhashi T; Oto T; Tabaru A; Otsuki M
Eur J Gastroenterol Hepatol; 2008 May; 20(5):373-8. PubMed ID: 18403937
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of joint detection of serum VEGF, SIL-2R and HGF in patients with primary hepatocellular carcinoma before and after percutaneous microwave coagulation therapy.
Chen JD; Xiong YQ; Dong K; Luo J; Yue LX; Chen Q
Asian Pac J Cancer Prev; 2014; 15(11):4545-8. PubMed ID: 24969882
[TBL] [Abstract][Full Text] [Related]
35. Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level.
Akaza H; Tsukamoto T; Fujioka T; Tomita Y; Kitamura T; Ozono S; Miki T; Naito S; Zembutsu H; Nakamura Y
Jpn J Clin Oncol; 2011 Aug; 41(8):1023-30. PubMed ID: 21642665
[TBL] [Abstract][Full Text] [Related]
36. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.
Kuusk T; Albiges L; Escudier B; Grivas N; Haanen J; Powles T; Bex A
Angiogenesis; 2017 May; 20(2):205-215. PubMed ID: 28401381
[TBL] [Abstract][Full Text] [Related]
37. Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models.
Cui S
Med Sci Monit; 2017 Jul; 23():3360-3366. PubMed ID: 28697172
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
[TBL] [Abstract][Full Text] [Related]
39. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.
Desar IM; Stillebroer AB; Oosterwijk E; Leenders WP; van Herpen CM; van der Graaf WT; Boerman OC; Mulders PF; Oyen WJ
J Nucl Med; 2010 Nov; 51(11):1707-15. PubMed ID: 20956472
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-2, interferon-alpha and medroxyprogesterone acetate in metastatic renal cell carcinoma.
Naglieri E; Lopez M; Lelli G; Morelli F; Amodio A; Di Tonno P; Gebbia N; Di Seri M; Chetri MC; Rizzo P; Abbate I; Casamassima A; Selvaggi FP; Colucci G
Anticancer Res; 2002; 22(5):3045-51. PubMed ID: 12530040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
